SCHEMBL23554192

SCHEMBL23554192

CCc1cccc(/N=N/c2cc(C(=O)O)cc(C(=O)O)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.53
ALDH1A1 P00352 4/20 0.44
MAPT P10636 7/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
THRB P10828 2/20 0.43
NOS3 P29474 2/20 0.43
NOS1 P29475 2/20 0.43
NOS2 P35228 2/20 0.43
PLCG1 P19174 1/20 0.43
TRPA1 O75762 1/20 0.43
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
GFER P55789 1/20 0.42
RXRA P19793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21887188 0.92 BCL2 (0.54) BCL2ALDH1A1MAPTMEN1KMT2A
SCHEMBL17707286 0.81 SIGMAR1 (0.50) NOS1NOS2SIGMAR1GRIN2DGRIN3B
SCHEMBL17707285 0.81 SIGMAR1 (0.50) NOS1NOS2SIGMAR1GRIN2DGRIN3B
SCHEMBL21887190 0.80 RAB9A (0.49) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL46935 0.76 BCL2 (0.66) BCL2ALDH1A1RAB9APKMSMN1; SMN2
SCHEMBL30394310 0.76 BCL2 (0.66) BCL2ALDH1A1RAB9APKMSMN1; SMN2
SCHEMBL28424644 0.76 CCNE2 (0.50) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL28424645 0.76 CCNE2 (0.50) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL31045928 0.75 RAB9A (0.65) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL69865 0.75 RAB9A (0.65) ALDH1A1MAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021127301-A1 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS Ikena Oncology, Inc. (US) 2021-06-24 WO disclosed